MeSH D014402 - tuberous sclerosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D020752:Neurocutaneous syndromes
0 Companies
0 Drugs
Success rate
D065703:Group i malformations of cortical development
0 Companies
0 Drugs
Success rate
D009378:Multiple primary neoplasms
0 Companies
0 Drugs
Success rate
D009386:Hereditary neoplastic syndromes
0 Companies
0 Drugs
Success rate
D020271:Nervous system heredodegenerative disorders
0 Companies
0 Drugs
Success rate
D006222:Hamartoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Everolimus | Votubia |  | 2011-09-02 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
100%4/4
Phase 2
40%4/10
Phase 3
50%3/6
Approved: 1Overall Success rate: 20%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use